Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children. Every year, an estimated one million children and young adolescents become ill with tuberculosis, and around 226,000 of those children die. Xpert MTB/RIF Ultra (Xpert Ultra) is a molecular World Health Organization (WHO)-recommended rapid diagnostic test that simultaneously detects Mycobacterium tuberculosis complex and rifampicin resistance. We previously published a Cochrane Review 'Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for tuberculosis disease and rifampicin resistance in children'. The current review updates evidence on the diagnostic accuracy of Xpert Ultra in children presumed to have tuberculosis disease. Parts of this review update informed the 2022 WHO updated guidance on management
Clinical commissioning policy: bedaquiline (B), pretomanid (Pa), linezolid (L) +/- moxifloxacin (M) (BPaLM/BPaL) for patients aged ?14 years with suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB NHS England » Clinical commissioning policy: bedaquiline (B), pretomanid (Pa), linezolid (L) +/- moxifloxacin (M) (BPaLM/BPaL) for patients aged ≥14 years with suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB or pre-extensively drug resistant (pre-XDR) TB [URN: 2310] Skip to main content Cookies on the NHS England websiteWe’ve put some small files called cookies on your device to make our site work. We’d also like to use analytics cookies. These send information about how our site
Clinical commissioning policy statement (2317): treatment for defined patients with rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB, pre-extensively drug-resistant (pre-XDR) TB and extensively drug-resistant (XDR-TB) including b NHS England » Clinical commissioning policy statement (2317): treatment for defined patients with rifampicin resistant (RR) tuberculosis (TB policy statement (2317): treatment for defined patients with rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB, pre-extensively drug-resistant (pre-XDR) TB and extensively drug-resistant (XDR-TB) including bedaquiline and delamanid (all ages)Document first published: 28 June 2024 Page updated: 28 June 2024 Topic: Publication type: Policy or strategy Clinical commissioning policy
Use of bedaquiline in children and adolescents with multidrug- and rifampicin-resistant tuberculosis: information note 1Use of bedaquiline in children and adolescents with multidrug- and rifampicin-resistant tuberculosis - Information noteBEDAQUILINEObjectiveTo provide practical guidance on the administration of bedaquiline in children and adolescents in the context of the treatment of multidrug - and rifampicin-resistant tuberculosis (MDR/RR-TB), in line with the latest World Health Organization (WHO) recommendations, dosing guidance and available formulations.Target audienceDoctors, clinicians, paediatricians, nurses, pharmacists, parents and caregivers of children with MDR/RR-TB, community health workers, programme managers, implementing partners and partners providing technical assistance.WHO
Use of delamanid in children and adolescents with multidrug- and rifampicin-resistant tuberculosis: information note 1Use of delamanid in children and adolescents with multidrug- and rifampicin-resistant tuberculosis - Information noteWHO recommendations for delamanid in children and adolescentsThe European Medicines Agency granted conditional approval to delamanid in 2014 “as part and Adolescents (6).Delamanid can be used as part of individualized longer regimens for people of all ages with MDR/RR-TB.ObjectiveTo provide practical guidance on the administration of delamanid in children and adolescents in the context of the treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB), in line with the latest World Health Organization (WHO) recommendations, dosing guidance
Treatment of MDR, pre-XDR, XDR and rifampicin-resistant tuberculosis or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment to the 2022 consensus-based guideline: Tuberculosis in adulthood by the German Central C Based on the assessment of new evidence, the World Health Organization (WHO) updated its guidelines for the treatment of drug-resistant tuberculosis (TB) in December 2022. The new recommendations and the latest study data made it necessary to update the existing guideline on the treatment of at least rifampicin- (RR-TB) for the German-speaking countries, replacing the respective chapters of the treatment guidelines published 2022. A shortened treatment of proven RR-TB and multidrug-resistant (MDR)-TB for at least 6 months using the fixed
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children. Every year, at least one million children become ill with tuberculosis and around 200,000 children die. Xpert MTB/RIF and Xpert Ultra are World Health Organization (WHO)-recommended rapid molecular tests that simultaneously detect tuberculosis and rifampicin resistance in adults to have tuberculosis; (b) tuberculous meningitis in children presumed to have tuberculosis; (c) lymph node tuberculosis in children presumed to have tuberculosis; and (d) rifampicin resistance in children presumed to have tuberculosis - For tuberculosis detection, index tests were used as the initial test, replacing standard practice (i.e. smear microscopy or culture) - For detection of rifampicin
Impact of rpoB gene mutations and Rifampicin-resistance levels on treatment outcomes in Rifampicin-resistant tuberculosis. Although many studies have examined the connection between mutations in the rpoB gene and drug resistance, the impact of common mutations on treatment outcomes for RR-TB is not yet fully understood. This study explores the relationship between rpoB gene mutations and drug -resistant phenotypes, assesses their role in predicting RR-TB prognosis, and investigates the impact of disputed rpoB mutations in M. tuberculosis on treatment outcomes. 192 rifampicin-resistant isolates were retested for drug susceptibility and gene sequencing. Minimum inhibitory concentrations (MICs) were determined for 98 isolates with disputed rpoB gene mutations. These mutations can cause low-level
Four months daily rifampicin versus three months daily rifampicin/isoniazid for the treatment of tuberculosis infection in asylum seekers: a randomized controlled trial. Treatment of tuberculosis infection is a core intervention of the TB elimination strategy. The World Health Organization recommends both four months of daily rifampicin (4R) and three months of daily isoniazid/rifampicin (3HR % CI: -0·09-0·13). Dropout rates due to side effects (25/113 in 4R vs 27/112 in 3HR) and the overall rate of adverse events (47/113 in 4R vs 36/112 in 3HR) were not statistically different in the two groups. Four months of rifampicin was not superior, in term of completion rate, to three months of isoniazid/rifampicin for the treatment of tuberculosis infectiosn among asylum seekers in Italy
Rapid Testing for the Diagnosis of Pulmonary Tuberculosis and Rifampicin Resistance: A Review of Cost-Effectiveness Rapid Testing for the Diagnosis of Pulmonary Tuberculosis and Rifampicin Resistance: A Review of Cost-Effectiveness | CADTH Skip to main content * About * Collaboration/Outreach * Patient/Community * Careers * Contact * My CADTH * FR * Reports * Reports . Rapid Testing for the Diagnosis of Pulmonary Tuberculosis and Rifampicin Resistance: A Review of Cost-Effectiveness Copied to clipboard Rapid Testing for the Diagnosis of Pulmonary Tuberculosis and Rifampicin Resistance: A Review of Cost-Effectiveness ( Last Updated : February 19, 2021) Project Line: Health Technology Review Project Sub Line: Summary with Critical Appraisal Project Number: RC1328-000
Rifampicin and isoniazid resistance not promote fluoroquinolone resistance in Mycobacterium smegmatis. The emergence of drug-resistant Tuberculosis (TB) has made treatment challenging. Although fluoroquinolones (FQs) are used as key drugs in the treatment of multidrug-resistant tuberculosis (MDR-TB), the problem of FQs resistance is becoming increasingly serious. Rifampicin (RIF) resistance
In rifampicin-resistant TB, bedaquiline-containing regimens reduced unfavorable status vs. a control regimen at 132 wk. GIM/FP/GP: [Formula: see text] Infectious Disease: [Formula: see text] Pulmonology: [Formula: see text].
Correction: Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria. [This corrects the article DOI: 10.1371/journal.pone.0241065.].
Rapid and Simultaneous Tuberculosis and Antibiotic Susceptibility Testing for the Diagnosis of Pulmonary Tuberculosis and Rifampicin Resistance: A Review of Diagnostic Accuracy Rapid and Simultaneous Tuberculosis and Antibiotic Susceptibility Testing for the Diagnosis of Pulmonary Tuberculosis and Rifampicin Resistance: A Review of Diagnostic Accuracy | CADTH Skip to main content * About @cadth.ca * About * Collaboration/Outreach * Patient/Community * Careers * Contact * My CADTH Breadcrumb 1. Home 2. Rapid and Simultaneous Tuberculosis and Antibiotic Susceptibility Testing for the Diagnosis of Pulmonary Tuberculosis and Rifampicin Resistance: A Review of Diagnostic Accuracy Copied to clipboard Rapid and Simultaneous Tuberculosis and Antibiotic Susceptibility Testing
Rifampicin You need to be logged in to see the full monograph.LoginUSE OF RIFAMPICIN IN PREGNANCYDate of issue: November 2022, Version: 3A corresponding patient information leaflet on USE OF RIFAMPICIN IN PREGNANCY is available.Rifampicin is a semisynthetic antibacterial drug used in the treatment of tuberculosis, leprosy, brucellosis, Legionnaire’s disease, Haemophilus influenza, and serious staphylococcal infections. Rifampicin is also used as prophylaxis against meningococcal meningitis, and off-license for pruritis caused by intrahepatic cholestasis of pregnancy.There are very limited data relating to fetal risks following exposure to rifampicin during pregnancy. No increased risks of miscarriage, congenital malformation, preterm delivery or low birth weight have been attributed to rifampicin
Pharmaceutical cost dynamics for the treatment of rifampicin-resistant tuberculosis in children and adolescents in South Africa, India, and the Philippines. Rifampicin-resistant (RR) tuberculosis (TB) in children is a major global health concern but is often neglected in economics research. Accurate cost estimations across the spectrum of paediatric RR-TB treatment regimens are critical inputs
Management of rifampicin-resistant tuberculosis in conflict-affected areas: The case of Iraq. Since December 2019, the World Health Organization (WHO) has encouraged National Tuberculosis Programs to deprioritize the use of injectable-containing regimens and roll-out all-oral bedaquiline-containing regimens for rifampicin-resistant tuberculosis (RR-TB) treatment. Consequently, Iraq gradually
The pattern of rpoB gene mutation of Mycobacterium tuberculosis and predictors of rifampicin resistance detected by GeneXpert MTB/RIF assay in Tanzania. Antimicrobial resistance in Mycobacterium tuberculosis (MTB) poses a significant challenge to tuberculosis (TB) management worldwide. Rifampicin resistance (RR) has been associated with the rpoB gene mutation. No study was conducted in Tanzania odds of developing rifampicin resistance (AOR 3.88, 95%CI: 1.80-8.32). RR was nearly nine times higher in previously treated patients than new patients (AOR 8.66, 95% CI: 6.97-10.76). HIV-positive individuals had nearly twice the odds of developing RR than HIV-negative individuals (AOR 1.91, 95%CI: 1.51-2.42). The rate of RR was lower compared to other studies in Tanzania, with probe E mutations
A machine-learning based model for automated recommendation of individualized treatment of rifampicin-resistant tuberculosis. Rifampicin resistant tuberculosis remains a global health problem with almost half a million new cases annually. In high-income countries patients empirically start a standardized treatment regimen, followed by an individualized regimen guided by drug susceptibility test
Trends of Mycobacterium tuberculosis and rifampicin resistance at the Ho Teaching Hospital in Ghana. Tuberculosis remains a major public health threat worldwide, causing significant morbidity and mortality, particularly in low- and middle-income countries. In recent years, efforts to combat tuberculosis have focused on strengthening healthcare systems and increasing access to diagnostics and treatment services. There is scarcity of data on the prevalence of Mycobacterium tuberculosis and rifampicin-resistant tuberculosis in the Volta region of Ghana. Therefore, the aim of this study was to determine the trends of Mycobacterium tuberculosis and rifampicin resistance in a major teaching hospital in Ghana spanning a six-year period. A retrospective cross-sectional hospital study was conducted